Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 6.49 3.84% 0.24
ADMS closed up 3.84 percent on Thursday, December 12, 2019, on approximately normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
See historical ADMS trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 3.84%
Overbought Stochastic Strength 3.84%
Bearish Engulfing Bearish -0.61%
Upper Bollinger Band Walk Strength -0.61%
Wide Bands Range Expansion -0.61%
Overbought Stochastic Strength -0.61%
Older signals for ADMS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Chemical Compounds Alzheimer's Disease Influenza Parkinson's Disease Psychiatry Psychiatric Diagnosis Dementia Treatment Of Alzheimer's Disease Cognitive Disorders Drug Therapy Chronic Disorders Learning Disabilities Levodopa Induced Dyskinesia Traumatic Brain Injury

Is ADMS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Dec 13 Glancy Prongay & Murray LLP Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors
Dec 12 INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors
Dec 12 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, WSG and BZUN
Dec 12 IMPORTANT INVESTOR REMINDER: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Dec 12 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, WSG and BZUN
Dec 12 NOTICE FROM THE FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Dec 12 ADMS INVESTOR ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Adamas Pharmaceuticals, Inc.
Dec 12 NOTICE FROM THE FILING LAW FIRM: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Dec 11 ADMS LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. – ADMS
Dec 11 CLASS ACTION UPDATE for ADMS, XYF and BZUN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
See more ADMS news...

Indicators

Indicator Value
52 Week High 12.57
52 Week Low 3.35
Average Volume 460,855
200-Day Moving Average 5.91
50-Day Moving Average 4.92
20-Day Moving Average 5.95
10-Day Moving Average 6.39
Average True Range 0.37
ADX 43.25
+DI 24.70
-DI 10.40
Chandelier Exit (Long, 3 ATRs ) 5.77
Chandelier Exit (Short, 3 ATRs ) 6.29
Upper Bollinger Band 6.88
Lower Bollinger Band 5.01
Percent B (%b) 0.79
BandWidth 31.43
MACD Line 0.42
MACD Signal Line 0.40
MACD Histogram 0.0188
Fundamentals Value
Market Cap 146.12 Million
Num Shares 22.5 Million
EPS -2.99
Price-to-Earnings (P/E) Ratio -2.17
Price-to-Sales 2373.51
Price-to-Book 4.03
PEG Ratio -0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.06
Resistance 3 (R3) 7.01 6.78 6.97
Resistance 2 (R2) 6.78 6.63 6.80 6.93
Resistance 1 (R1) 6.63 6.54 6.71 6.68 6.90
Pivot Point 6.40 6.40 6.43 6.42 6.40
Support 1 (S1) 6.25 6.25 6.33 6.30 6.08
Support 2 (S2) 6.02 6.16 6.04 6.05
Support 3 (S3) 5.87 6.02 6.02
Support 4 (S4) 5.92